Europe – Page 24 – pharmaceutical daily

March 8, 2022 Off

Stevanato Group Reports Record 2021 Revenue of €843.9 million

– Establishes Full Year 2022 Guidance – PIOMBINO DESE, Italy–(BUSINESS WIRE)–Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of…

March 8, 2022 Off

Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress

By Dino Mustafić

Basilea Pharmaceutica Ltd. has reported that preclinical data on the single agent anti-cancer activity of the drug candidate BAL0891 have been presented at the Targeted Anticancer Therapies congress 2022 of the European Society of Medical Oncology (ESMO TAT 2022), which is taking place online March 7-8, 2022.

March 8, 2022 Off

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

By Dino Mustafić

NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an…

March 8, 2022 Off

Publication of Definitive Interim Result for Vifor Pharma Tender Offer: CSL Behring AG Declares Offer Successful

By Dino Mustafić

CSL Behring AG, a wholly-owned subsidiary of global biotechnology leader CSL Limited has announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

March 8, 2022 Off

Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

By Dino Mustafić

Valneva SE has announced successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.

March 7, 2022 Off

Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for Skin Cancer Drug

By Dino Mustafić

Evaxion Biotech has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients.

March 7, 2022 Off

Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise

By Dino Mustafić

In this newly created role reporting to the CEO, Dr. Yver will be accountable for the company’s overall development strategy, including scientific, clinical and regulatory matters, and will continue to provide support to research and clinical development teams.